ReviewBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2014
Association among genetic predisposition, gut microbiota, and host immune response in the etiopathogenesis of inflammatory bowel disease.
Review in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04105348 (The Association of Diabetes Mellitus and Inflammatory Bowel Disease), which is not on this map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Association of Diabetes Mellitus and Inflammatory Bowel Disease
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Methodological Quality Assessment of Meta-Analyses and Systematic Reviews of Probiotics in Inflammatory Bowel Disease and Pouchitis.PloS one · 2016Pooled it
- Intermittent Administration of Helminth-Derived Fh15 Modulates Gut Microbiota and Partially Mitigates Dysbiosis in Early Stages of Severe Experimental Colitis.International journal of molecular sciences · 2026Article
- Review
- Multimodal deep learning for inflammatory bowel disease: a new frontier in cellular and molecular biomarker discovery to clinical translation.Journal of biological engineering · 2026Review
- Article
- WTAP-mediated mHuman cell · 2025Article
- Lipidomics, Microbiota, and IntestinalInternational journal of molecular sciences · 2025Review
- Article
- Investigation ofAfrican health sciences · 2025Article
- Cellular senescence defining the disease characteristics of Crohn's disease.Frontiers in immunology · 2025Article
- Article
- Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis.Science translational medicine · 2023Article
- Immunomodulatory effects of different strains of Lactococcus lactis in DSS-induced colitis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- Leaky Gut and the Ingredients That Help Treat It: A Review.Molecules (Basel, Switzerland) · 2023Review
- Protective effect of α7 nicotinic acetylcholine receptor activation on experimental colitis and its mechanism.Molecular medicine (Cambridge, Mass.) · 2022Article
- The Incidence of Inflammatory Bowel Disease in the Paediatric Population in the District of Lower Silesia, Poland.Journal of clinical medicine · 2021Article
- Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy.World journal of stem cells · 2020Review
- Article
- Increased Risk of Diabetes in Inflammatory Bowel Disease Patients: A Nationwide Population-based Study in Korea.Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic disorder that affects thousands of people around the world. These diseases are characterized by exacerbated uncontrolled intestinal inflammation that leads to poor quality of life in affected patients. Although the exact cause of IBD still remains unknown, compelling evidence suggests that the interplay among immune deregulation, environmental factors, and genetic polymorphisms contributes to the multifactorial nature of the disease. Therefore, in this review we present classical and novel findings regarding IBD etiopathogenesis. Considering the genetic causes of the diseases, alterations in about 100 genes or allelic variants, most of them in components of the immune system, have been related to IBD susceptibility. Dysbiosis of the intestinal microbiota also plays a role in the initiation or perpetuation of gut inflammation, which develops under altered or impaired immune responses. In this context, unbalanced innate and especially adaptive immunity has been considered one of the major contributing factors to IBD development, with the involvement of the Th1, Th2, and Th17 effector population in addition to impaired regulatory responses in CD or UC. Finally, an understanding of the interplay among pathogenic triggers of IBD will improve knowledge about the immunological mechanisms of gut inflammation, thus providing novel tools for IBD control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.